Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Tiziana Life Sciences Ltd.

< Previous 1 2 3 4 Next >
News headline image
Tiziana Life Sciences Announces Appointment of William A. Clementi as Chief Development Officer
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
News headline image
Tiziana Life Sciences Announces Foralumab Presentation by Dr. Howard Weiner at the Annual Meeting of the International Society of Neuroimmunology
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
News headline image
Tiziana Life Sciences Announces Live Bloomberg TV Interview of Renowned Scientist Dr. Howard L. Weiner to Discuss FDA IND Clearance for Intranasal Foralumab in Alzheimer's Disease
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
News headline image
Tiziana Life Sciences Announces FDA IND Clearance of Intranasal Foralumab for the Treatment of Alzheimer’s Disease
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
News headline image
Tiziana Life Sciences Ltd. Receives Nasdaq Deficiency Notice
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
News headline image
Tiziana Life Sciences Promotes Matthew W. Davis, MD, RPh to Chief Operating Officer
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
News headline image
Tiziana Life Sciences Announces Reduction in Microglial Activation in a Total of 5 Out of 6 Intranasal Foralumab Expanded Access Patients with Non-Active Secondary Progressive Multiple Sclerosis
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
News headline image
Tiziana Life Sciences to Host KOL Webinar on Foralumab in Non-Active Secondary Progressive Multiple Sclerosis (SPMS)
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
News headline image
Tiziana Life Sciences Announces Participation on the Webull Corporate Communications Service Platform
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
News headline image
Tiziana Life Sciences Announces Chief Medical Officer Invited to Give Presentation on Intranasal Foralumab on May 17
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
News headline image
Tiziana Life Sciences Announces Findings from Intranasal Anti-CD3 mAb Treatment in Intracerebral Hemorrhage at the Annual American Academy of Neurology Conference
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
News headline image
Tiziana Life Sciences Ltd Reports Annual Results for the Twelve Months Ended December 31, 2022, and Corporate Update
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
News headline image
Tiziana Life Sciences Ltd. Regains Compliance with Nasdaq Listing Minimum Bid Price Rule
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
News headline image
Tiziana Life Sciences to File Alzheimer’s IND for Intranasal Foralumab in Q2 2023
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
News headline image
Tiziana Life Sciences Initiates Program to Develop Intranasal Foralumab in Type 1 Diabetes
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
News headline image
Tiziana Life Sciences to Pursue Development of Intranasal Foralumab for the Treatment of Long COVID
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
News headline image
Tiziana Life Sciences Announces Presentations on Intranasal Foralumab at the “Preserving the Brain” Scientific Conference and Exhibit at Prada Rong Zhai in Shanghai
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
News headline image
Tiziana Life Sciences Announces Invitation for Podium Presentation of Research on Intranasal Anti-CD3 mAb in Intracerebral Hemorrhage at the Annual American Academy of Neurology Conference
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
News headline image
Tiziana Announces Positive Data on Intranasal Anti-CD3 Monoclonal Antibody in Intracerebral Hemorrhage
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
News headline image
Tiziana Life Sciences Announces Anti-CD3 mAb Research for the Treatment of Alzheimer’s Disease to be Presented by Dr. Howard Weiner at the International Conference on Alzheimer’s and Parkinson’s Disease and Related Neurological Disorders Conference in
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
News headline image
Tiziana Life Sciences to Proceed with Phase 2 Clinical Trial in Patients with Non-Active Secondary Progressive Multiple Sclerosis (SPMS)
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
News headline image
Tiziana Life Sciences Announces Purchase of Common Shares by Chairman and Acting CEO
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
News headline image
Tiziana Life Sciences Announces Purchase of Common Shares by Chairman and Acting CEO
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
News headline image
Tiziana Life Sciences Announces Purchase of Common Shares by Chairman and Acting CEO
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
News headline image
Tiziana Life Sciences Announces Purchase of Common Shares by Chairman and Acting CEO
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
News headline image
Tiziana Life Sciences Highlighted in Forbes Article
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
News headline image
Tiziana Life Sciences Announces Publication in Proceedings of the National Academy of Sciences (PNAS) Illustrating the Immunological Basis of the Mechanism of Action for Intranasal Foralumab
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
News headline image
Tiziana Life Sciences Announces IND filed for Phase 2 Study of Milciclib in Combination with Gemcitabine for Non-Small Cell Lung Cancer
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
News headline image
Tiziana Life Sciences Announces Additional Clinical Improvements in the Second Patient with Non-Active Secondary Progressive Multiple Sclerosis (SPMS) After Eleven Months of Dosing with Intranasal Foralumab
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
News headline image
Tiziana Life Sciences Ltd (“Tiziana” or “the Company”) - Updated Interim Results for the Six Months Ended 30 June 2022
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS